Does Medicare Advantage Cover Metformin?

How Medicare Advantage Part D Handles Metformin for Diabetes

Medicare Advantage plans that include Part D drug benefits are required by the Centers for Medicare and Medicaid Services (CMS) to cover metformin when it is prescribed for type 2 diabetes. Metformin has carried FDA approval for that indication since 1994, and every CMS-approved formulary must include at least one drug in each therapeutic category the agency designates as essential. Metformin sits firmly in the biguanide category, meaning plans cannot simply drop it.

The FDA-approved label for metformin hydrochloride confirms use in adults and pediatric patients aged 10 and older for glycemic control in type 2 diabetes mellitus [1]. The American Diabetes Association's 2024 Standards of Care designate metformin as a preferred initial pharmacologic agent for type 2 diabetes in the absence of contraindications [2]. That clinical consensus strengthens a coverage argument considerably if a plan attempts to restrict access.

In UKPDS 34 (N=1,704), overweight patients with type 2 diabetes assigned to intensive metformin therapy showed a 32% reduction in diabetes-related endpoints and an 11% reduction in all-cause mortality compared with conventional treatment over a median 10.7-year follow-up (P<0.001) [3]. That trial remains the cornerstone outcomes evidence supporting metformin as a first-line agent and is routinely cited by payers in their own formulary rationale.

Most plans place generic metformin immediate-release and extended-release on Tier 1, meaning the standard copay ranges from $0 to $10 per 30-day supply. A 90-day mail-order fill often costs the same or less. If your Explanation of Benefits shows a higher tier, you may request a formulary exception in writing citing the ADA guideline recommendation, which plans are obligated to consider under 42 CFR 423.578 [4].

Why Medicare Advantage Does Not Cover Metformin for Weight Loss Alone

Federal law draws a hard line here. Under 42 CFR 423.100, Part D plans are prohibited from covering drugs used for cosmetic purposes or weight loss. The statute treats a drug's covered indication as the reason written on the prescription, not the drug's pharmacology. So even though observational data and the Diabetes Prevention Program Outcomes Study (DPPOS, N=2,776 at 15-year follow-up) show metformin reduces progression from prediabetes to diabetes and modestly reduces body weight, a prescription written explicitly for weight loss will be denied [5].

There is one narrow exception worth knowing. CMS issued guidance in March 2024 clarifying that semaglutide 2.4 mg (Wegovy) may be covered under Part D when prescribed for its FDA-approved cardiovascular outcomes indication following the SELECT trial. That exception applies to semaglutide, not to metformin, because metformin does not carry a separate cardiovascular outcomes label in the United States [6].

If your prescriber documents your diagnosis as type 2 diabetes or prediabetes with a supporting HbA1c or fasting glucose value, the prescription aligns with an FDA-approved indication, and the coverage determination changes entirely. Prediabetes alone does not guarantee approval, but a documented HbA1c of 5.7% to 6.4% with a prescriber note citing the ADA's recommendation for metformin in high-risk prediabetes (BMI <35, age <60, history of gestational diabetes) can support a medical necessity argument [2].

Understanding Prior Authorization for Metformin on Medicare Advantage

Prior authorization (PA) for generic metformin in the diabetes indication is uncommon but not impossible. A 2022 analysis published in JAMA Internal Medicine found that among Medicare Part D plans, generic drugs on Tier 1 carried PA requirements in fewer than 3% of instances, while specialty-tier drugs carried PA requirements in over 80% of instances [7]. Metformin's generic status means most fills go through without any PA paperwork.

When PA does appear, it is usually triggered by one of three scenarios: the prescribing diagnosis code does not match the formulary indication, the quantity requested exceeds the plan's days-supply limit (often 100 tablets per 30 days for 500 mg twice daily), or the prescriber submitted a non-preferred extended-release brand instead of the generic. Correcting the ICD-10 code to E11.9 (type 2 diabetes mellitus without complications) or E11.65 (type 2 diabetes with hyperglycemia) and resubmitting often resolves the issue in 24 to 48 hours.

The ADA's 2024 Standards of Care state: "Metformin remains the preferred initial pharmacologic agent for the treatment of type 2 diabetes given its effectiveness, safety, low cost, and potential cardiovascular benefits" [2]. Quoting that guideline language directly in a PA letter, alongside the patient's most recent HbA1c value and the prescriber's attestation that no contraindications exist (eGFR >30 mL/min/1.73m² is the standard threshold), gives the plan's medical director a clear clinical rationale to approve [8].

Step Therapy Requirements and How They Apply to Metformin

Step therapy for metformin is rare because metformin is the first step. CMS step-therapy rules under the Medicare Modernization Act require plans to allow exceptions when step therapy would cause adverse clinical effects or when a patient has already failed prior agents. Because metformin is the ADA-recommended starting drug for type 2 diabetes, a plan cannot require a patient to try a different agent before approving metformin without violating that standard [4].

Step therapy is more relevant in reverse: some plans require a trial of metformin before approving a GLP-1 receptor agonist or SGLT-2 inhibitor. In that context, documented metformin use or a documented contraindication (eGFR <30, lactic acidosis history, GI intolerance after dose titration attempts) becomes the prerequisite that unlocks access to the next-line agent.

A 2019 Cochrane review of metformin versus other active comparators in type 2 diabetes (including 13 trials, N=3,187) found no significant difference in HbA1c reduction between metformin and sulfonylureas at 12 months, but metformin was associated with less hypoglycemia and modest weight reduction [9]. Plans citing this evidence to justify sulfonylurea step therapy before metformin would face a difficult medical necessity challenge, since the ADA explicitly rates both as first-line but lists metformin as the preferred first choice [2].

What Formulary Tier Is Metformin On, and What Does That Mean for Your Copay?

Generic metformin immediate-release is a Tier 1 drug on the overwhelming majority of Medicare Advantage Part D formularies. Tier 1 drugs carry the lowest cost-sharing, typically $0 to $10 per 30-day fill. Metformin extended-release (ER) generics are usually Tier 1 as well, although a handful of plans place them on Tier 2 (preferred generic), which raises the copay to roughly $10 to $25.

The brand-name Glucophage and Glucophage XR are rarely covered at preferred tiers and may land on Tier 3 or Tier 4, where copays can reach $45 to $100 per fill. There is no clinical reason to use brand-name metformin over the generic: the FDA's Orange Book lists multiple metformin hydrochloride generics as therapeutically equivalent (AB-rated) to Glucophage [1]. Switching to the generic eliminates the tier penalty without any change in clinical effect.

To check your specific plan's tier, log into your plan's online formulary tool or call the member services number on the back of your card and ask for the formulary status of NDC 57237-0027 (one common metformin 500 mg generic NDC) or simply the drug name. CMS also maintains the Plan Finder tool at medicare.gov, which allows drug-by-drug formulary lookups across all enrolled plans [10].

During the Medicare Part D coverage gap (the "donut hole"), cost-sharing changes. In 2025, the Inflation Reduction Act's $2,000 out-of-pocket cap and redesigned benefit phases mean most Medicare beneficiaries taking a low-cost generic like metformin will never come close to triggering gap-phase pricing. The standard deductible for Part D in 2025 is $590, but plans may waive that deductible for Tier 1 and Tier 2 drugs [10].

How to Appeal a Medicare Advantage Denial of Metformin

A denial is not final. Medicare Advantage plans must follow a five-level appeals process established under 42 CFR Part 423, Subpart M [4]. The practical path for most metformin denials moves through three stages before reaching federal review.

Level 1: Plan internal review. Submit a Coverage Determination Request within 60 days of the denial notice. Include the prescriber's letter of medical necessity, the patient's most recent lab values (HbA1c, eGFR, basic metabolic panel), and a copy of the ADA 2024 guideline page recommending metformin as first-line therapy. For an expedited review (when delay would seriously jeopardize health), the plan must respond within 72 hours. Standard review requires 7 calendar days.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, request review by MAXIMUS Federal Services, the CMS-contracted IRE. You have 60 days from the plan's reconsideration notice. MAXIMUS reviews clinical evidence independently of the plan and overturns approximately 40% of Part D denials that reach that stage, according to CMS's annual Part D appeals data [10].

Level 3: Office of Medicare Hearings and Appeals (OMHA). If MAXIMUS upholds the denial and the amount in dispute exceeds $180 (adjusted annually), you may request an ALJ hearing. This stage rarely applies to metformin given its low cost, but the pathway exists.

The most common reason denials are reversed at Level 1 is documentation: the original claim lacked an ICD-10 code matching a covered indication, and adding one with a prescriber attestation resolves the issue. A 2021 OIG report found that Medicare Advantage plans denied 13% of prior authorization requests that met Medicare coverage rules, meaning a substantial share of denials are administrative errors that a single corrected submission can fix [11].

Cash-Pay and Patient Assistance Options When Coverage Fails

If an appeal is pending or coverage is denied for a non-covered indication, metformin is among the cheapest prescription drugs available in the United States. The cash price at major pharmacy chains and discount programs (GoodRx, Cost Plus Drugs, Walmart $4 program) runs $4 to $10 per 30-day supply for metformin 500 mg or 1 to 000 mg tablets. Extended-release generic formulations cost $8 to $20 per month cash.

Medicare beneficiaries cannot legally use manufacturer copay assistance cards for Part D-covered drugs. The Anti-Kickback Statute and OIG guidance prohibit manufacturers from subsidizing cost-sharing for federally insured patients [12]. That restriction applies even when a plan technically covers the drug. Because metformin's cash price is $4 to $10, the cost-sharing restriction matters very little in practice: the drug costs less out-of-pocket cash than most plan copays.

The Extra Help program (Low Income Subsidy) reduces or eliminates Part D cost-sharing for beneficiaries meeting income and asset thresholds (individual income below approximately $22 to 590 in 2025). Metformin under Extra Help may cost $0 to $4 per fill. Applications go through the Social Security Administration at ssa.gov.

Metformin Dosing, Safety, and Monitoring Under Medicare Coverage

Medicare coverage does not change the clinical requirements for safe prescribing, and payers increasingly audit lab compliance as a condition of continued coverage. The standard starting dose is metformin 500 mg once or twice daily with meals, titrated over 4 to 8 weeks to a target of 1,500 to 2 to 000 mg per day in divided doses [1]. The maximum labeled dose is 2 to 550 mg per day, though most patients achieve adequate glycemic control at 2 to 000 mg.

Renal function monitoring is required before starting and at least annually during therapy. The FDA updated the metformin label in 2016 to allow use in patients with eGFR as low as 30 mL/min/1.73m², replacing the older serum creatinine cutoffs. For eGFR 30 to 45, dose reduction and more frequent monitoring (every 3 to 6 months) are recommended. Metformin is contraindicated when eGFR falls below 30 [1].

Vitamin B12 deficiency is a documented long-term adverse effect. The DPPOS study showed that metformin use over 13 years was associated with a 4.3 percentage point higher prevalence of B12 deficiency compared with placebo (P<0.001) [5]. Annual B12 screening is recommended for patients on long-term metformin, and many Medicare Advantage plans cover serum B12 measurement under Part B as medically necessary monitoring for a patient on metformin.

Gastrointestinal side effects (nausea, diarrhea, abdominal cramping) affect roughly 25% to 30% of patients at initiation and are the leading reason for discontinuation. Switching from immediate-release to extended-release metformin at the same total daily dose reduces GI adverse events. A trial published in Diabetes Care (N=209) found the ER formulation reduced GI complaints by approximately 40% compared with IR at equivalent doses [13]. That clinical distinction matters if a plan's PA requires documentation of tolerability.

Special Populations: Prediabetes, Gestational Diabetes History, and PCOS

Metformin's FDA approval covers type 2 diabetes. Off-label uses including polycystic ovary syndrome (PCOS) and prediabetes are clinically supported but not guaranteed to receive Part D coverage.

For prediabetes, the DPP (N=3,234) showed metformin 850 mg twice daily reduced diabetes incidence by 31% over 2.8 years versus placebo (P<0.001) [14]. The ADA recommends considering metformin for high-risk prediabetes, particularly in patients aged <60 with BMI >35 or a history of gestational diabetes. However, a Part D plan may require the claim to be billed under an ICD-10 code that reflects either the prediabetes diagnosis (R73.09) or a covered comorbidity. Plans vary in whether they accept R73.09 alone as sufficient for coverage.

For PCOS, metformin is not FDA-approved, and Part D coverage is explicitly not guaranteed for non-indicated uses under 42 CFR 423.100. Some plans cover off-label metformin for PCOS if supported by a documented diagnosis of insulin resistance or impaired fasting glucose, but this requires plan-specific formulary exception documentation.

Women with a prior gestational diabetes diagnosis have a 10-year cumulative type 2 diabetes incidence approaching 50% in some cohorts [15]. For those patients, a prescribing physician documenting both the gestational diabetes history and current prediabetes markers (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%) builds the strongest possible coverage case under ADA guidelines.